Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.
BASKING RIDGE, N.J. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on its commercial operations, clinical development programs, and introduced select preliminary unaudited guidance for the fourth
BASKING RIDGE, N.J. , Dec. 27, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company’s current Chairman of the Board, Carrie S. Cox , will resign from the Board effective March 31, 2020 . Ms.
NICE has today published a medical technologies guidance document recommending the use of gammaCore within the NHS for the acute and preventive treatment of cluster headache in the U.K. LONDON and BASKING RIDGE, N.J. , Dec. 03, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a
BASKING RIDGE, N.J. , Nov. 26, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger , Chief Executive Officer, will present a corporate overview and host investor meetings at the Evercore ISI HealthCONx
Continued growth in prescribing physicians, paid months of therapy and dispensed prescriptions Company to host conference call and webcast today, November 13 , at 4:30pm ET BASKING RIDGE, N.J. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic
Conference Call to be Held at 4:30pm Eastern Time BASKING RIDGE, N.J. , Nov. 07, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third quarter and nine-months ended September 30,
BASKING RIDGE, N.J. , Sept. 30, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the appointment of Daniel S. Goldberger as Chief Executive Officer, effective October 1 . Mr.
Additional information requested by FDA; Premium 2 trial progressing as planned BASKING RIDGE, N.J. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR, or the “Company”), a commercial-stage bioelectronic medicine company, today announced that the U.S.
Sequential growth reported in paid months of therapy, prescribing physicians and prescriptions dispensed Company to host conference call and webcast today, August 13 , at 4:30pm ET BASKING RIDGE, N.J. , Aug. 13, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc.
BASKING RIDGE, N.J. , Aug. 12, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the company has entered into an exclusive contract with Doctor’s Medical, LLC for distribution rights to gammaCore for patients with workers’
